CAR- T细胞通道：金属蛋白酶工程CAR- T细胞穿过实体肿瘤

IF 8.2 1区医学 Q1 IMMUNOLOGY

Cancer immunology research Pub Date : 2025-10-08 DOI:10.1158/2326-6066.CIR-25-1097

Alessandro Gasparetto, Roberto Chiarle

{"title":"CAR- T细胞通道：金属蛋白酶工程CAR- T细胞穿过实体肿瘤","authors":"Alessandro Gasparetto, Roberto Chiarle","doi":"10.1158/2326-6066.CIR-25-1097","DOIUrl":null,"url":null,"abstract":"Overcoming the physical barriers of the tumor microenvironment remains a major obstacle for chimeric antigen receptor (CAR) T-cell therapy in solid tumors. In this issue, Van Pelt and colleagues show that engineering GD2-targeting CAR T cells to express matrix metalloproteinase 7 and osteopontin-b enhances their ability to infiltrate tumors rich in extracellular matrix. These modifications improve functionality in preclinical models without increasing off-target toxicity. The findings highlight a promising strategy to design CAR T cells with extracellular matrix-remodeling capabilities. See related article by Van Pelt et al., p. XX .","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":"OF1-OF2"},"PeriodicalIF":8.2000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CAR-ving a Path: Metalloprotease-Engineered CAR T Cells Tunnel through Solid Tumors.\",\"authors\":\"Alessandro Gasparetto, Roberto Chiarle\",\"doi\":\"10.1158/2326-6066.CIR-25-1097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Overcoming the physical barriers of the tumor microenvironment remains a major obstacle for chimeric antigen receptor (CAR) T-cell therapy in solid tumors. In this issue, Van Pelt and colleagues show that engineering GD2-targeting CAR T cells to express matrix metalloproteinase 7 and osteopontin-b enhances their ability to infiltrate tumors rich in extracellular matrix. These modifications improve functionality in preclinical models without increasing off-target toxicity. The findings highlight a promising strategy to design CAR T cells with extracellular matrix-remodeling capabilities. See related article by Van Pelt et al., p. XX .\",\"PeriodicalId\":9474,\"journal\":{\"name\":\"Cancer immunology research\",\"volume\":\" \",\"pages\":\"OF1-OF2\"},\"PeriodicalIF\":8.2000,\"publicationDate\":\"2025-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer immunology research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/2326-6066.CIR-25-1097\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer immunology research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2326-6066.CIR-25-1097","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

克服肿瘤微环境的物理障碍仍然是嵌合抗原受体（CAR） t细胞治疗实体瘤的主要障碍。在这一期中，Van Pelt和他的同事们表明，通过工程化gd2靶向CAR - T细胞表达基质金属蛋白酶7和骨桥蛋白-b，可以增强它们浸润富含细胞外基质的肿瘤的能力。这些修饰改善了临床前模型的功能，而不增加脱靶毒性。这些发现强调了一种设计具有细胞外基质重塑能力的CAR - T细胞的有希望的策略。参见Van Pelt等人的相关文章，第XX页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

CAR-ving a Path: Metalloprotease-Engineered CAR T Cells Tunnel through Solid Tumors.

Overcoming the physical barriers of the tumor microenvironment remains a major obstacle for chimeric antigen receptor (CAR) T-cell therapy in solid tumors. In this issue, Van Pelt and colleagues show that engineering GD2-targeting CAR T cells to express matrix metalloproteinase 7 and osteopontin-b enhances their ability to infiltrate tumors rich in extracellular matrix. These modifications improve functionality in preclinical models without increasing off-target toxicity. The findings highlight a promising strategy to design CAR T cells with extracellular matrix-remodeling capabilities. See related article by Van Pelt et al., p. XX .

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer immunology research ONCOLOGY-IMMUNOLOGY

CiteScore

15.60

自引率

1.00%

发文量

260

期刊介绍： Cancer Immunology Research publishes exceptional original articles showcasing significant breakthroughs across the spectrum of cancer immunology. From fundamental inquiries into host-tumor interactions to developmental therapeutics, early translational studies, and comprehensive analyses of late-stage clinical trials, the journal provides a comprehensive view of the discipline. In addition to original research, the journal features reviews and opinion pieces of broad significance, fostering cross-disciplinary collaboration within the cancer research community. Serving as a premier resource for immunology knowledge in cancer research, the journal drives deeper insights into the host-tumor relationship, potent cancer treatments, and enhanced clinical outcomes. Key areas of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and insightful clinical investigations with immunological implications.